Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)

被引：0
|
作者：
Fontana, A.
Bocci, G.
Galli, L.
Derosa, L.
Minuti, G.
D'Arcangelo, M.
Santini, D.
Landi, L.
Bursi, S.
Falcone, A.
机构：
[1] ASL6, Livorno, Italy
[2] Univ Pisa, ITT, Pisa, Italy
[3] ASL6, ITT, Livorno, Italy
[4] Univ Campus Bio Med, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16032
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of abiraterone acetate plus prednisone in patients with castration resistant prostate cancer (CRPC) and no prior therapy with ketoconazole
    Ryan, C.
    Harzstark, A.
    Fong, L.
    Lin, A.
    Kilian, C.
    Molina, A.
    Small, E. J.
    EJC SUPPLEMENTS, 2008, 6 (12): : 81 - 81
  • [42] Docetaxel in combination with Temsirolimus in patients with advanced castration resistant prostate cancer (CRPC): A phase II trial of the Spanish Oncology Genitourinary Group
    Duran, I.
    Rodriguez-Moreno, J. F.
    Lainez, N.
    Climent Duran, M. A.
    Leon, L.
    Garcia-Carbonero, I.
    Garcia-Donas, J.
    Viqueira, A.
    Bellmunt, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S704 - S704
  • [43] EFFECTIVENESS OF DOCETAXEL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER IN THE FIRST TREATMENT LINE
    Villa, J. C.
    Espinosa, J.
    Gomez, R.
    Sanchez, V
    Lopez, R.
    Galan, R.
    Pineda, M. D.
    Perez, M.
    VALUE IN HEALTH, 2015, 18 (07) : A816 - A817
  • [44] A PHASE I STUDY OF ORAL PANOBINOSTAT (LBH589) ALONE AND IN COMBINATION WITH DOCETAXEL (DOC) AND PREDNISONE IN CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Rathkopf, D. E.
    Wong, B. Y.
    Ross, R. W.
    George, D. J.
    Picus, J.
    Atadja, P.
    Yang, W.
    Culver, K. W.
    Woo, M. M.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2008, 19 : 199 - 200
  • [45] A phase I study of oral panobinostat (LBH589) alone and in combination with docetaxel (Doc) and prednisone in castration-resistant prostate cancer (CRPC)
    Rathkopf, D. E.
    Wong, B. Y.
    Ross, R. W.
    George, D. J.
    Picus, J.
    Tanaka, E.
    Chen, Y.
    Atadja, P.
    Yang, W.
    Culver, K. W.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (CRPC) after failure of docetaxel-based chemotherapy
    Danila, D. C.
    Rathkopf, D. E.
    Morris, M. J.
    Slovin, S. F.
    Schwartz, L. H.
    Farmer, K.
    Anand, A.
    Haqq, C.
    Fleisher, M.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Phase II multicenter study of abiraterone acetate (AA) plus prednisone therapy in docetaxel-treated castration-resistant prostate cancer (CRPC) patients (pts): Impact of prior ketoconazole (keto)
    Danila, D. C.
    de Bono, J.
    Ryan, C. J.
    Denmeade, S.
    Smith, M.
    Taplin, M.
    Bubley, G.
    Molina, A.
    Haqq, C.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Phase I/II study of MDV3100 in patients (pts) with progressive castration-resistant prostate cancer (CRPC)
    Scher, H. I.
    Beer, T. M.
    Higano, C. S.
    Danila, D. C.
    Montgomery, B.
    Shelkey, J.
    Hirmand, M.
    Hung, D.
    Sawyers, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [49] Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first-line treatment of metastatic castration-resistant prostate cancer
    Passildas-Jahanmohan, Judith
    Eymard, Jean-Christophe
    Pouget, Melanie
    Kwiatkowski, Fabrice
    Van Praagh, Isabelle
    Savareux, Laurent
    Atger, Marc
    Durando, Xavier
    Abrial, Catherine
    Richard, Damien
    Ginzac Couve, Angeline
    Thivat, Emilie
    Monange, Brigitte
    Chollet, Philippe
    Mahammedi, Hakim
    CANCER MEDICINE, 2021, 10 (07): : 2332 - 2340
  • [50] A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC)
    Chi, Kim N.
    Hotte, Sebastien J.
    Ellard, Susan
    Gingerich, Joel Roger
    Joshua, Anthony Michael
    Yu, Evan Y.
    Gleave, Martin Edwin
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345